Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 269 | 2024 | 17346 | 8.670 |
Why?
|
Anti-HIV Agents | 110 | 2024 | 4524 | 6.400 |
Why?
|
Cost-Benefit Analysis | 147 | 2024 | 5492 | 4.340 |
Why?
|
Anti-Retroviral Agents | 34 | 2023 | 1782 | 3.130 |
Why?
|
AIDS-Related Opportunistic Infections | 41 | 2015 | 662 | 3.120 |
Why?
|
Antiretroviral Therapy, Highly Active | 42 | 2019 | 1896 | 2.950 |
Why?
|
CD4 Lymphocyte Count | 88 | 2021 | 2569 | 2.900 |
Why?
|
Life Expectancy | 50 | 2024 | 1242 | 2.440 |
Why?
|
Health Care Costs | 43 | 2022 | 3243 | 2.010 |
Why?
|
Mass Screening | 40 | 2021 | 5428 | 1.940 |
Why?
|
South Africa | 65 | 2024 | 1841 | 1.790 |
Why?
|
Acquired Immunodeficiency Syndrome | 21 | 2022 | 2199 | 1.580 |
Why?
|
Computer Simulation | 45 | 2024 | 6236 | 1.570 |
Why?
|
Quality-Adjusted Life Years | 37 | 2024 | 1722 | 1.520 |
Why?
|
Homosexuality, Male | 18 | 2024 | 1334 | 1.300 |
Why?
|
Communicable Disease Control | 6 | 2024 | 849 | 1.280 |
Why?
|
AIDS Serodiagnosis | 12 | 2016 | 220 | 1.170 |
Why?
|
Infectious Disease Transmission, Vertical | 14 | 2023 | 1351 | 1.130 |
Why?
|
Benzoxazines | 6 | 2024 | 316 | 1.100 |
Why?
|
Viral Load | 25 | 2024 | 3330 | 1.050 |
Why?
|
Tuberculosis | 16 | 2021 | 2016 | 0.990 |
Why?
|
Chemoprevention | 8 | 2016 | 326 | 0.960 |
Why?
|
Models, Economic | 15 | 2020 | 716 | 0.950 |
Why?
|
HIV | 20 | 2023 | 1582 | 0.930 |
Why?
|
Heterocyclic Compounds, 3-Ring | 4 | 2024 | 285 | 0.930 |
Why?
|
HIV-1 | 29 | 2023 | 6860 | 0.920 |
Why?
|
Medication Adherence | 7 | 2020 | 2176 | 0.890 |
Why?
|
Ambulatory Care Facilities | 9 | 2020 | 934 | 0.880 |
Why?
|
Drug Resistance, Viral | 12 | 2020 | 861 | 0.860 |
Why?
|
Drug Monitoring | 6 | 2018 | 961 | 0.860 |
Why?
|
Models, Theoretical | 22 | 2024 | 3577 | 0.830 |
Why?
|
Adult | 183 | 2024 | 221122 | 0.810 |
Why?
|
RNA, Viral | 23 | 2018 | 2846 | 0.790 |
Why?
|
HIV Integrase Inhibitors | 3 | 2020 | 165 | 0.780 |
Why?
|
Disease Transmission, Infectious | 5 | 2017 | 559 | 0.760 |
Why?
|
Humans | 330 | 2024 | 761326 | 0.760 |
Why?
|
Male | 194 | 2024 | 360621 | 0.750 |
Why?
|
Drug Costs | 16 | 2020 | 1183 | 0.750 |
Why?
|
Cote d'Ivoire | 16 | 2023 | 64 | 0.740 |
Why?
|
Models, Biological | 23 | 2021 | 9468 | 0.710 |
Why?
|
Developing Countries | 10 | 2022 | 2887 | 0.700 |
Why?
|
Drug Resistance, Multiple, Viral | 1 | 2020 | 53 | 0.690 |
Why?
|
Patient Compliance | 10 | 2017 | 2690 | 0.680 |
Why?
|
Female | 199 | 2024 | 392485 | 0.680 |
Why?
|
India | 11 | 2022 | 2349 | 0.660 |
Why?
|
Nevirapine | 5 | 2015 | 273 | 0.650 |
Why?
|
Mobile Health Units | 3 | 2015 | 92 | 0.640 |
Why?
|
Health Resources | 8 | 2019 | 935 | 0.620 |
Why?
|
Policy | 1 | 2022 | 508 | 0.610 |
Why?
|
Hepatitis B | 4 | 2024 | 707 | 0.580 |
Why?
|
Nigeria | 9 | 2023 | 770 | 0.570 |
Why?
|
Cohort Studies | 52 | 2022 | 41440 | 0.560 |
Why?
|
Clinical Laboratory Techniques | 6 | 2020 | 747 | 0.540 |
Why?
|
Antiviral Agents | 10 | 2024 | 3057 | 0.540 |
Why?
|
United States | 75 | 2024 | 72317 | 0.530 |
Why?
|
Pneumonia, Pneumocystis | 6 | 2002 | 242 | 0.530 |
Why?
|
Budgets | 5 | 2020 | 230 | 0.520 |
Why?
|
Housing | 1 | 2020 | 670 | 0.520 |
Why?
|
Continuity of Patient Care | 10 | 2022 | 1069 | 0.510 |
Why?
|
Point-of-Care Systems | 8 | 2019 | 1212 | 0.500 |
Why?
|
Urban Health Services | 1 | 2016 | 177 | 0.500 |
Why?
|
Drug Substitution | 1 | 2018 | 289 | 0.500 |
Why?
|
Adenine | 8 | 2020 | 987 | 0.500 |
Why?
|
Universities | 1 | 2020 | 994 | 0.500 |
Why?
|
Hepatitis C | 5 | 2019 | 1584 | 0.490 |
Why?
|
Models, Statistical | 13 | 2020 | 5078 | 0.490 |
Why?
|
Hepatitis B, Chronic | 3 | 2024 | 410 | 0.470 |
Why?
|
Antifungal Agents | 4 | 2017 | 752 | 0.460 |
Why?
|
Lamivudine | 3 | 2024 | 365 | 0.460 |
Why?
|
Hepatitis C, Chronic | 5 | 2015 | 1032 | 0.460 |
Why?
|
Anti-Infective Agents | 7 | 2009 | 984 | 0.450 |
Why?
|
Patient Acceptance of Health Care | 10 | 2016 | 3204 | 0.440 |
Why?
|
Lost to Follow-Up | 5 | 2020 | 123 | 0.430 |
Why?
|
Viremia | 1 | 2016 | 707 | 0.430 |
Why?
|
Middle Aged | 87 | 2024 | 220774 | 0.430 |
Why?
|
Health Services Accessibility | 9 | 2017 | 5439 | 0.410 |
Why?
|
Emigrants and Immigrants | 2 | 2016 | 543 | 0.410 |
Why?
|
Smoking Cessation | 5 | 2024 | 2056 | 0.400 |
Why?
|
Glucuronosyltransferase | 1 | 2012 | 131 | 0.400 |
Why?
|
Abnormalities, Drug-Induced | 2 | 2012 | 339 | 0.400 |
Why?
|
Office Visits | 1 | 2016 | 595 | 0.400 |
Why?
|
Oxazines | 4 | 2024 | 349 | 0.390 |
Why?
|
Dideoxynucleosides | 3 | 2024 | 134 | 0.390 |
Why?
|
Primary Health Care | 9 | 2017 | 4685 | 0.390 |
Why?
|
Prevalence | 25 | 2022 | 15719 | 0.380 |
Why?
|
Behavior Therapy | 2 | 2015 | 880 | 0.380 |
Why?
|
Antibodies, Heterophile | 2 | 2001 | 128 | 0.370 |
Why?
|
Dementia | 2 | 2024 | 2686 | 0.370 |
Why?
|
Delivery of Health Care | 7 | 2021 | 5334 | 0.370 |
Why?
|
Infectious Mononucleosis | 2 | 2001 | 133 | 0.370 |
Why?
|
HIV Protease Inhibitors | 4 | 2007 | 432 | 0.370 |
Why?
|
Delivery of Health Care, Integrated | 2 | 2019 | 942 | 0.360 |
Why?
|
Sensitivity and Specificity | 30 | 2021 | 14665 | 0.350 |
Why?
|
Drugs, Generic | 5 | 2024 | 448 | 0.350 |
Why?
|
Resource Allocation | 3 | 2009 | 350 | 0.350 |
Why?
|
Alkynes | 6 | 2024 | 320 | 0.350 |
Why?
|
Decision Support Techniques | 12 | 2020 | 1998 | 0.350 |
Why?
|
Genotype | 11 | 2020 | 12982 | 0.340 |
Why?
|
Mycobacterium avium-intracellulare Infection | 3 | 1999 | 76 | 0.340 |
Why?
|
Cyclopropanes | 6 | 2024 | 432 | 0.340 |
Why?
|
World Health Organization | 8 | 2014 | 1320 | 0.330 |
Why?
|
Microbial Sensitivity Tests | 5 | 2015 | 1956 | 0.330 |
Why?
|
Bacteriological Techniques | 1 | 2010 | 279 | 0.330 |
Why?
|
Risk-Taking | 5 | 2013 | 1037 | 0.330 |
Why?
|
Young Adult | 40 | 2024 | 59196 | 0.320 |
Why?
|
Ganciclovir | 2 | 2001 | 252 | 0.320 |
Why?
|
Substance Abuse, Intravenous | 4 | 2023 | 530 | 0.320 |
Why?
|
Public Health | 6 | 2024 | 2667 | 0.320 |
Why?
|
Zimbabwe | 5 | 2022 | 135 | 0.320 |
Why?
|
Pyridones | 4 | 2024 | 808 | 0.310 |
Why?
|
Treatment Failure | 9 | 2017 | 2642 | 0.300 |
Why?
|
Ribavirin | 5 | 2015 | 395 | 0.290 |
Why?
|
State Health Plans | 3 | 2009 | 219 | 0.290 |
Why?
|
Survival Analysis | 17 | 2019 | 10075 | 0.290 |
Why?
|
Delayed Diagnosis | 1 | 2011 | 462 | 0.290 |
Why?
|
HIV Seropositivity | 4 | 2013 | 960 | 0.290 |
Why?
|
Drug Administration Schedule | 9 | 2020 | 4850 | 0.290 |
Why?
|
Uterine Cervical Neoplasms | 3 | 2014 | 2019 | 0.290 |
Why?
|
Patient-Centered Care | 1 | 2017 | 1419 | 0.290 |
Why?
|
Sputum | 8 | 2021 | 506 | 0.280 |
Why?
|
Group Homes | 2 | 2024 | 59 | 0.280 |
Why?
|
Quality Indicators, Health Care | 2 | 2017 | 1792 | 0.280 |
Why?
|
Lipopolysaccharides | 4 | 2021 | 2206 | 0.280 |
Why?
|
Mycoses | 6 | 2007 | 386 | 0.280 |
Why?
|
Hospitalization | 5 | 2024 | 10715 | 0.280 |
Why?
|
Africa South of the Sahara | 6 | 2021 | 743 | 0.280 |
Why?
|
Guidelines as Topic | 7 | 2017 | 1385 | 0.280 |
Why?
|
Monte Carlo Method | 7 | 2024 | 1257 | 0.270 |
Why?
|
Mycobacterium tuberculosis | 4 | 2019 | 1913 | 0.270 |
Why?
|
Tuberculosis, Pulmonary | 3 | 2019 | 832 | 0.270 |
Why?
|
Early Diagnosis | 9 | 2021 | 1184 | 0.270 |
Why?
|
Cost of Illness | 8 | 2007 | 1935 | 0.270 |
Why?
|
Adolescent | 44 | 2024 | 88305 | 0.260 |
Why?
|
Pentamidine | 3 | 2002 | 44 | 0.260 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3200 | 0.260 |
Why?
|
Drug Therapy, Combination | 11 | 2012 | 6309 | 0.260 |
Why?
|
Secondary Prevention | 1 | 2012 | 1474 | 0.260 |
Why?
|
Incidence | 17 | 2024 | 21336 | 0.260 |
Why?
|
Treatment Outcome | 36 | 2020 | 64645 | 0.260 |
Why?
|
Motivation | 1 | 2015 | 2006 | 0.260 |
Why?
|
Brazil | 4 | 2024 | 1230 | 0.250 |
Why?
|
Community Health Services | 3 | 2018 | 656 | 0.250 |
Why?
|
Cytomegalovirus Infections | 4 | 2002 | 831 | 0.240 |
Why?
|
Medical Assistance | 2 | 2002 | 108 | 0.240 |
Why?
|
Markov Chains | 11 | 2015 | 965 | 0.240 |
Why?
|
Diagnostic Tests, Routine | 5 | 2021 | 787 | 0.240 |
Why?
|
Quinolizines | 1 | 2024 | 20 | 0.240 |
Why?
|
Azocines | 1 | 2024 | 20 | 0.240 |
Why?
|
AIDS Vaccines | 2 | 2016 | 896 | 0.240 |
Why?
|
Immunotherapy, Active | 1 | 2004 | 59 | 0.240 |
Why?
|
Time Factors | 22 | 2018 | 39974 | 0.230 |
Why?
|
Ritonavir | 4 | 2015 | 329 | 0.230 |
Why?
|
Public Sector | 3 | 2019 | 267 | 0.230 |
Why?
|
Dapsone | 2 | 2002 | 56 | 0.220 |
Why?
|
Public Health Administration | 1 | 2006 | 243 | 0.220 |
Why?
|
Piperazines | 4 | 2024 | 2519 | 0.220 |
Why?
|
Decision Support Systems, Clinical | 1 | 2012 | 1175 | 0.220 |
Why?
|
Alkaloids | 1 | 2024 | 192 | 0.210 |
Why?
|
Clinical Trials as Topic | 10 | 2023 | 7999 | 0.210 |
Why?
|
Quality of Life | 18 | 2024 | 13355 | 0.210 |
Why?
|
Antibodies, Monoclonal | 1 | 2020 | 9180 | 0.210 |
Why?
|
Kenya | 3 | 2022 | 758 | 0.210 |
Why?
|
Forecasting | 5 | 2024 | 2928 | 0.210 |
Why?
|
Voluntary Programs | 4 | 2011 | 48 | 0.210 |
Why?
|
Program Evaluation | 6 | 2015 | 2494 | 0.210 |
Why?
|
Risk Factors | 31 | 2024 | 74152 | 0.200 |
Why?
|
Financing, Government | 1 | 2006 | 472 | 0.200 |
Why?
|
Boston | 11 | 2010 | 9333 | 0.200 |
Why?
|
Practice Guidelines as Topic | 7 | 2012 | 7389 | 0.200 |
Why?
|
Naphthoquinones | 1 | 2002 | 58 | 0.200 |
Why?
|
Genetic Testing | 2 | 2012 | 3538 | 0.200 |
Why?
|
Patient Dropouts | 2 | 2020 | 412 | 0.200 |
Why?
|
Depression | 3 | 2023 | 8122 | 0.200 |
Why?
|
CD4-Positive T-Lymphocytes | 6 | 2013 | 4371 | 0.200 |
Why?
|
Quarantine | 1 | 2024 | 181 | 0.200 |
Why?
|
Massachusetts | 10 | 2024 | 8837 | 0.190 |
Why?
|
France | 6 | 2012 | 498 | 0.190 |
Why?
|
Antiprotozoal Agents | 1 | 2002 | 94 | 0.190 |
Why?
|
Reverse Transcriptase Inhibitors | 6 | 2020 | 621 | 0.190 |
Why?
|
Infant | 18 | 2023 | 36202 | 0.190 |
Why?
|
Alcohol-Related Disorders | 1 | 2004 | 238 | 0.190 |
Why?
|
Patient Simulation | 2 | 2020 | 298 | 0.190 |
Why?
|
Preventive Health Services | 1 | 2006 | 567 | 0.190 |
Why?
|
Thyroiditis | 1 | 2001 | 86 | 0.190 |
Why?
|
Community Health Centers | 3 | 2021 | 461 | 0.190 |
Why?
|
Europe | 3 | 2023 | 3420 | 0.180 |
Why?
|
Antibodies, Viral | 3 | 2020 | 3155 | 0.170 |
Why?
|
Outpatient Clinics, Hospital | 4 | 2007 | 395 | 0.170 |
Why?
|
Models, Econometric | 4 | 2007 | 216 | 0.170 |
Why?
|
Breast Feeding | 4 | 2018 | 1358 | 0.170 |
Why?
|
Pregnancy | 19 | 2024 | 29858 | 0.170 |
Why?
|
Iodide Peroxidase | 1 | 2001 | 294 | 0.170 |
Why?
|
Disease Progression | 15 | 2015 | 13500 | 0.170 |
Why?
|
Direct Service Costs | 3 | 2006 | 59 | 0.170 |
Why?
|
Insurance, Pharmaceutical Services | 1 | 2002 | 348 | 0.170 |
Why?
|
Alcoholism | 3 | 2005 | 1973 | 0.170 |
Why?
|
Fees and Charges | 1 | 2020 | 192 | 0.170 |
Why?
|
Interferons | 2 | 2014 | 705 | 0.160 |
Why?
|
Sarcoma, Kaposi | 1 | 2022 | 374 | 0.160 |
Why?
|
Health Knowledge, Attitudes, Practice | 5 | 2019 | 4014 | 0.160 |
Why?
|
Cause of Death | 3 | 2017 | 3685 | 0.160 |
Why?
|
Regression Analysis | 7 | 2016 | 6341 | 0.160 |
Why?
|
Herpesvirus 4, Human | 2 | 2001 | 1079 | 0.160 |
Why?
|
Botswana | 1 | 2022 | 1048 | 0.160 |
Why?
|
Protease Inhibitors | 2 | 2012 | 753 | 0.150 |
Why?
|
HLA-B Antigens | 2 | 2010 | 331 | 0.150 |
Why?
|
Infant, Newborn | 13 | 2024 | 26211 | 0.150 |
Why?
|
Masks | 1 | 2020 | 208 | 0.150 |
Why?
|
Infant Care | 1 | 2019 | 180 | 0.150 |
Why?
|
Travel | 1 | 2024 | 796 | 0.150 |
Why?
|
Serologic Tests | 1 | 2020 | 384 | 0.150 |
Why?
|
Colposcopy | 1 | 1999 | 150 | 0.150 |
Why?
|
Asymptomatic Infections | 1 | 2019 | 131 | 0.150 |
Why?
|
National Health Programs | 2 | 2019 | 440 | 0.150 |
Why?
|
Drug Combinations | 3 | 2024 | 2048 | 0.150 |
Why?
|
Thyrotropin | 1 | 2001 | 835 | 0.150 |
Why?
|
Smoking | 4 | 2020 | 9051 | 0.150 |
Why?
|
Outpatients | 5 | 2018 | 1596 | 0.140 |
Why?
|
Zidovudine | 4 | 2015 | 624 | 0.140 |
Why?
|
Nystatin | 1 | 2017 | 22 | 0.140 |
Why?
|
Postnatal Care | 1 | 2019 | 262 | 0.140 |
Why?
|
Gentian Violet | 1 | 2017 | 26 | 0.140 |
Why?
|
HIV Seroprevalence | 2 | 2011 | 89 | 0.140 |
Why?
|
Candidiasis, Oral | 1 | 2017 | 57 | 0.140 |
Why?
|
Fluconazole | 1 | 1997 | 157 | 0.140 |
Why?
|
Public Health Practice | 1 | 2019 | 219 | 0.140 |
Why?
|
Urban Population | 5 | 2017 | 2033 | 0.130 |
Why?
|
Cultural Competency | 1 | 2019 | 300 | 0.130 |
Why?
|
Child | 21 | 2024 | 80156 | 0.130 |
Why?
|
United States Food and Drug Administration | 1 | 2024 | 1665 | 0.130 |
Why?
|
Observation | 1 | 2017 | 310 | 0.130 |
Why?
|
Medically Uninsured | 1 | 2001 | 835 | 0.130 |
Why?
|
Demography | 4 | 2015 | 1648 | 0.130 |
Why?
|
Vaginal Smears | 1 | 1999 | 499 | 0.130 |
Why?
|
Comprehensive Health Care | 1 | 2016 | 123 | 0.130 |
Why?
|
HIV Fusion Inhibitors | 2 | 2006 | 82 | 0.130 |
Why?
|
Patents as Topic | 1 | 2016 | 111 | 0.130 |
Why?
|
Cryptococcus | 1 | 2015 | 28 | 0.130 |
Why?
|
Research Personnel | 1 | 2020 | 588 | 0.120 |
Why?
|
Developmental Disabilities | 1 | 2024 | 1508 | 0.120 |
Why?
|
Counseling | 5 | 2013 | 1546 | 0.120 |
Why?
|
Malnutrition | 2 | 2014 | 644 | 0.120 |
Why?
|
Pneumocystis | 1 | 1995 | 55 | 0.120 |
Why?
|
Hepatitis B virus | 3 | 2024 | 529 | 0.120 |
Why?
|
Antigens, Fungal | 1 | 2015 | 69 | 0.120 |
Why?
|
Melanoma | 2 | 2007 | 5706 | 0.120 |
Why?
|
Statistics, Nonparametric | 2 | 2016 | 2853 | 0.120 |
Why?
|
Circumcision, Male | 1 | 2016 | 148 | 0.120 |
Why?
|
Government Programs | 2 | 2007 | 279 | 0.120 |
Why?
|
Epidemics | 1 | 2020 | 511 | 0.120 |
Why?
|
Uridine Monophosphate | 1 | 2015 | 68 | 0.120 |
Why?
|
Africa | 2 | 2014 | 710 | 0.120 |
Why?
|
Inpatients | 2 | 2006 | 2548 | 0.120 |
Why?
|
Poverty | 1 | 2006 | 2697 | 0.120 |
Why?
|
Cryptococcosis | 1 | 2015 | 104 | 0.120 |
Why?
|
Delayed-Action Preparations | 2 | 2015 | 962 | 0.120 |
Why?
|
Pregnancy Complications, Infectious | 6 | 2021 | 2152 | 0.120 |
Why?
|
Retrospective Studies | 16 | 2021 | 80575 | 0.120 |
Why?
|
Health Education | 1 | 2001 | 1052 | 0.120 |
Why?
|
Rural Population | 4 | 2018 | 2283 | 0.120 |
Why?
|
Condoms | 1 | 2016 | 331 | 0.120 |
Why?
|
Sexual Behavior | 7 | 2024 | 2179 | 0.120 |
Why?
|
Liver Function Tests | 2 | 2012 | 522 | 0.120 |
Why?
|
Prenatal Diagnosis | 1 | 2001 | 1265 | 0.110 |
Why?
|
Mycobacterium Infections | 2 | 2006 | 122 | 0.110 |
Why?
|
Alcohol Drinking | 3 | 2004 | 4027 | 0.110 |
Why?
|
Skin Neoplasms | 2 | 2007 | 5820 | 0.110 |
Why?
|
HIV Envelope Protein gp41 | 2 | 2006 | 303 | 0.110 |
Why?
|
Tuberculosis, Multidrug-Resistant | 2 | 2012 | 935 | 0.110 |
Why?
|
Pyrrolidinones | 1 | 2014 | 116 | 0.110 |
Why?
|
Epidemiologic Research Design | 1 | 2017 | 368 | 0.110 |
Why?
|
Patients | 1 | 2020 | 906 | 0.110 |
Why?
|
Child, Preschool | 9 | 2022 | 42251 | 0.110 |
Why?
|
Gross Domestic Product | 1 | 2013 | 78 | 0.110 |
Why?
|
Stavudine | 2 | 2010 | 85 | 0.110 |
Why?
|
Medically Underserved Area | 1 | 2015 | 256 | 0.110 |
Why?
|
Geographic Information Systems | 1 | 2015 | 281 | 0.110 |
Why?
|
Antibodies | 1 | 2001 | 2421 | 0.110 |
Why?
|
Risk Assessment | 8 | 2022 | 23981 | 0.110 |
Why?
|
Hepatitis B e Antigens | 2 | 2024 | 133 | 0.110 |
Why?
|
Decision Making | 5 | 2020 | 3929 | 0.110 |
Why?
|
Infant Mortality | 1 | 2018 | 759 | 0.110 |
Why?
|
Interprofessional Relations | 1 | 2019 | 991 | 0.110 |
Why?
|
HIV Antibodies | 4 | 2023 | 1303 | 0.110 |
Why?
|
Prospective Studies | 16 | 2023 | 54405 | 0.100 |
Why?
|
Physician's Role | 1 | 1999 | 916 | 0.100 |
Why?
|
HIV Reverse Transcriptase | 3 | 2009 | 212 | 0.100 |
Why?
|
Decision Trees | 5 | 2009 | 504 | 0.100 |
Why?
|
Health Policy | 5 | 2024 | 2684 | 0.100 |
Why?
|
Liver Cirrhosis | 3 | 2024 | 1934 | 0.100 |
Why?
|
Aged | 19 | 2024 | 169179 | 0.100 |
Why?
|
Hepacivirus | 2 | 2017 | 1337 | 0.100 |
Why?
|
Antigen Presentation | 2 | 2010 | 1254 | 0.100 |
Why?
|
Interferon-alpha | 4 | 2015 | 921 | 0.100 |
Why?
|
Self Care | 1 | 2017 | 796 | 0.100 |
Why?
|
Hepatitis C Antibodies | 1 | 2012 | 146 | 0.100 |
Why?
|
Patient Transfer | 1 | 2019 | 793 | 0.100 |
Why?
|
Cardiovascular Diseases | 2 | 2017 | 15499 | 0.100 |
Why?
|
Patient Participation | 1 | 2001 | 1443 | 0.100 |
Why?
|
Drug Resistance, Bacterial | 1 | 2019 | 1058 | 0.100 |
Why?
|
Geography | 2 | 2013 | 658 | 0.100 |
Why?
|
Pandemics | 5 | 2024 | 8635 | 0.100 |
Why?
|
Bacterial Infections | 4 | 2007 | 1406 | 0.090 |
Why?
|
Treatment Refusal | 2 | 2006 | 429 | 0.090 |
Why?
|
Specialization | 1 | 2016 | 779 | 0.090 |
Why?
|
Vaccination | 2 | 2022 | 3381 | 0.090 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2024 | 2299 | 0.090 |
Why?
|
State Government | 2 | 2006 | 384 | 0.090 |
Why?
|
International Cooperation | 1 | 2017 | 1428 | 0.090 |
Why?
|
Cross-Sectional Studies | 8 | 2022 | 26108 | 0.090 |
Why?
|
Tuberculin Test | 1 | 2011 | 206 | 0.090 |
Why?
|
Microscopy | 2 | 2019 | 902 | 0.090 |
Why?
|
Pyrimidinones | 2 | 2011 | 385 | 0.090 |
Why?
|
Skin Diseases | 1 | 1999 | 1092 | 0.090 |
Why?
|
Recurrence | 4 | 2020 | 8470 | 0.090 |
Why?
|
Teratogens | 1 | 2011 | 117 | 0.090 |
Why?
|
Mental Health Services | 1 | 2022 | 1730 | 0.090 |
Why?
|
Candidiasis | 2 | 2008 | 365 | 0.090 |
Why?
|
Genes, MHC Class I | 1 | 2010 | 240 | 0.090 |
Why?
|
Quality Improvement | 2 | 2017 | 3800 | 0.090 |
Why?
|
Pharmacogenetics | 2 | 2011 | 675 | 0.090 |
Why?
|
Aged, 80 and over | 8 | 2024 | 58946 | 0.080 |
Why?
|
Reminder Systems | 1 | 2012 | 388 | 0.080 |
Why?
|
Public Assistance | 1 | 2009 | 47 | 0.080 |
Why?
|
False Positive Reactions | 3 | 2020 | 956 | 0.080 |
Why?
|
Patient Selection | 1 | 2001 | 4244 | 0.080 |
Why?
|
Systems Integration | 1 | 2011 | 426 | 0.080 |
Why?
|
Multivariate Analysis | 7 | 2018 | 12059 | 0.080 |
Why?
|
Follow-Up Studies | 12 | 2019 | 39108 | 0.080 |
Why?
|
Survival Rate | 3 | 2012 | 12710 | 0.080 |
Why?
|
Age Distribution | 2 | 2023 | 2880 | 0.080 |
Why?
|
Appointments and Schedules | 1 | 2012 | 443 | 0.080 |
Why?
|
Primary Prevention | 1 | 2016 | 1186 | 0.080 |
Why?
|
Latent Tuberculosis | 1 | 2011 | 224 | 0.080 |
Why?
|
Immunoassay | 1 | 2012 | 746 | 0.080 |
Why?
|
Sentinel Surveillance | 2 | 2007 | 292 | 0.080 |
Why?
|
Polymerase Chain Reaction | 3 | 2010 | 6086 | 0.080 |
Why?
|
Oligopeptides | 1 | 2014 | 1186 | 0.080 |
Why?
|
HIV Antigens | 2 | 2010 | 325 | 0.080 |
Why?
|
Data Collection | 3 | 2011 | 3324 | 0.080 |
Why?
|
Logistic Models | 5 | 2018 | 13251 | 0.080 |
Why?
|
Methotrexate | 1 | 1995 | 1720 | 0.080 |
Why?
|
Diagnostic Services | 1 | 2007 | 34 | 0.080 |
Why?
|
Value of Life | 2 | 2001 | 98 | 0.080 |
Why?
|
Self Report | 2 | 2017 | 3724 | 0.080 |
Why?
|
Health Services Research | 1 | 2015 | 1811 | 0.070 |
Why?
|
Liver Neoplasms | 1 | 2024 | 4321 | 0.070 |
Why?
|
Health Expenditures | 1 | 2020 | 2365 | 0.070 |
Why?
|
Hemoglobins, Abnormal | 1 | 2008 | 119 | 0.070 |
Why?
|
Aging | 2 | 2024 | 8704 | 0.070 |
Why?
|
DNA, Viral | 3 | 2024 | 2201 | 0.070 |
Why?
|
Disabled Persons | 2 | 2024 | 1225 | 0.070 |
Why?
|
Meningitis, Cryptococcal | 1 | 2008 | 67 | 0.070 |
Why?
|
Health Care Rationing | 3 | 2017 | 437 | 0.070 |
Why?
|
Medical Informatics | 1 | 2014 | 733 | 0.070 |
Why?
|
Toxoplasmosis, Cerebral | 1 | 2006 | 19 | 0.070 |
Why?
|
Mozambique | 2 | 2017 | 55 | 0.070 |
Why?
|
Telemedicine | 1 | 2024 | 3041 | 0.070 |
Why?
|
Staining and Labeling | 1 | 2010 | 1085 | 0.070 |
Why?
|
Public Policy | 1 | 2010 | 559 | 0.070 |
Why?
|
Stem Cell Transplantation | 1 | 2014 | 1598 | 0.070 |
Why?
|
Anus Neoplasms | 2 | 2000 | 329 | 0.060 |
Why?
|
Hospitals, Municipal | 2 | 1995 | 19 | 0.060 |
Why?
|
DNA, Bacterial | 1 | 2010 | 1481 | 0.060 |
Why?
|
Internationality | 1 | 2011 | 1001 | 0.060 |
Why?
|
Dideoxyadenosine | 1 | 2024 | 9 | 0.060 |
Why?
|
Proportional Hazards Models | 5 | 2024 | 12450 | 0.060 |
Why?
|
Behavioral Risk Factor Surveillance System | 1 | 2006 | 208 | 0.060 |
Why?
|
Self Disclosure | 1 | 2006 | 249 | 0.060 |
Why?
|
Disclosure | 2 | 2023 | 748 | 0.060 |
Why?
|
Drug Utilization | 1 | 2011 | 1188 | 0.060 |
Why?
|
Calibration | 2 | 2020 | 818 | 0.060 |
Why?
|
Drug Therapy | 2 | 2020 | 503 | 0.060 |
Why?
|
Referral and Consultation | 3 | 2012 | 3597 | 0.060 |
Why?
|
Health Behavior | 2 | 2012 | 2641 | 0.060 |
Why?
|
Private Sector | 1 | 2007 | 397 | 0.060 |
Why?
|
Sulfonamides | 1 | 2014 | 1976 | 0.060 |
Why?
|
Diagnostic Techniques and Procedures | 1 | 2006 | 219 | 0.060 |
Why?
|
Antitubercular Agents | 3 | 2020 | 1375 | 0.060 |
Why?
|
Federal Government | 1 | 2006 | 267 | 0.060 |
Why?
|
Rifampin | 2 | 2019 | 339 | 0.060 |
Why?
|
Opioid-Related Disorders | 1 | 2019 | 2160 | 0.060 |
Why?
|
Needlestick Injuries | 1 | 2004 | 71 | 0.060 |
Why?
|
Longitudinal Studies | 3 | 2010 | 14597 | 0.060 |
Why?
|
HLA Antigens | 1 | 2009 | 1371 | 0.060 |
Why?
|
Drug Discovery | 1 | 2012 | 1054 | 0.060 |
Why?
|
Medical Records Systems, Computerized | 1 | 2010 | 1192 | 0.060 |
Why?
|
Internal Medicine | 1 | 2011 | 1051 | 0.060 |
Why?
|
Gene Products, gag | 1 | 2004 | 312 | 0.060 |
Why?
|
Mental Disorders | 1 | 2023 | 6839 | 0.060 |
Why?
|
Odds Ratio | 4 | 2013 | 9639 | 0.050 |
Why?
|
Predictive Value of Tests | 5 | 2011 | 15262 | 0.050 |
Why?
|
Ambulatory Care | 4 | 2011 | 2775 | 0.050 |
Why?
|
Peptide Fragments | 2 | 2006 | 5114 | 0.050 |
Why?
|
Prisoners | 1 | 2006 | 314 | 0.050 |
Why?
|
Heterosexuality | 2 | 2016 | 309 | 0.050 |
Why?
|
Pneumonia | 1 | 1995 | 2140 | 0.050 |
Why?
|
Prognosis | 3 | 2019 | 29588 | 0.050 |
Why?
|
Toxoplasmosis | 2 | 2007 | 94 | 0.050 |
Why?
|
Biopsy | 1 | 1995 | 6768 | 0.050 |
Why?
|
Registries | 2 | 2016 | 8223 | 0.050 |
Why?
|
Ukraine | 1 | 2023 | 149 | 0.050 |
Why?
|
Chickenpox | 1 | 2003 | 96 | 0.050 |
Why?
|
Parasitic Diseases | 1 | 2003 | 76 | 0.050 |
Why?
|
Hepatitis B Surface Antigens | 1 | 2024 | 302 | 0.050 |
Why?
|
Analgesics, Opioid | 1 | 2019 | 3801 | 0.050 |
Why?
|
Siblings | 1 | 2007 | 825 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3080 | 0.050 |
Why?
|
Ethambutol | 2 | 2012 | 59 | 0.050 |
Why?
|
Atovaquone | 1 | 2002 | 56 | 0.050 |
Why?
|
HIV Long-Term Survivors | 3 | 2010 | 121 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 1 | 2012 | 6473 | 0.050 |
Why?
|
Polyethylene Glycols | 1 | 2008 | 1188 | 0.050 |
Why?
|
Statistics as Topic | 1 | 2008 | 2358 | 0.050 |
Why?
|
Risk | 4 | 2015 | 9605 | 0.050 |
Why?
|
Social Stigma | 2 | 2023 | 769 | 0.050 |
Why?
|
Lead Poisoning | 2 | 1995 | 322 | 0.050 |
Why?
|
Hospitals | 2 | 2017 | 3878 | 0.050 |
Why?
|
Multicenter Studies as Topic | 1 | 2006 | 1703 | 0.050 |
Why?
|
Health Services | 1 | 2006 | 752 | 0.050 |
Why?
|
Bleomycin | 1 | 2022 | 494 | 0.050 |
Why?
|
Age Factors | 2 | 2016 | 18401 | 0.050 |
Why?
|
Bisexuality | 2 | 2000 | 294 | 0.050 |
Why?
|
Biomedical Research | 1 | 2016 | 3429 | 0.050 |
Why?
|
Physicians | 1 | 2019 | 4591 | 0.050 |
Why?
|
Sex Distribution | 1 | 2006 | 2281 | 0.050 |
Why?
|
Etoposide | 1 | 2022 | 634 | 0.050 |
Why?
|
Pharmaceutical Services | 1 | 2002 | 141 | 0.050 |
Why?
|
Financial Management | 1 | 2002 | 160 | 0.050 |
Why?
|
Algorithms | 4 | 2014 | 14025 | 0.050 |
Why?
|
Morbidity | 3 | 2012 | 1750 | 0.050 |
Why?
|
Data Interpretation, Statistical | 2 | 2017 | 2691 | 0.050 |
Why?
|
Insurance Coverage | 2 | 2002 | 1938 | 0.050 |
Why?
|
Isoniazid | 2 | 2012 | 283 | 0.040 |
Why?
|
Reproducibility of Results | 7 | 2014 | 20092 | 0.040 |
Why?
|
Anonymous Testing | 1 | 1999 | 9 | 0.040 |
Why?
|
Florida | 1 | 2001 | 431 | 0.040 |
Why?
|
Patient Satisfaction | 1 | 2012 | 3460 | 0.040 |
Why?
|
Health Status Indicators | 2 | 2003 | 968 | 0.040 |
Why?
|
Mortality | 3 | 2019 | 2898 | 0.040 |
Why?
|
Vincristine | 1 | 2022 | 1036 | 0.040 |
Why?
|
Leukoplakia, Hairy | 1 | 1999 | 9 | 0.040 |
Why?
|
Amino Acid Substitution | 1 | 2004 | 1737 | 0.040 |
Why?
|
Malaria | 2 | 2007 | 1227 | 0.040 |
Why?
|
History, 21st Century | 1 | 2006 | 1567 | 0.040 |
Why?
|
Medicaid | 2 | 2005 | 2817 | 0.040 |
Why?
|
Cost Savings | 3 | 2015 | 913 | 0.040 |
Why?
|
Folliculitis | 1 | 1999 | 25 | 0.040 |
Why?
|
Arthritis, Rheumatoid | 1 | 1995 | 3760 | 0.040 |
Why?
|
HIV Seronegativity | 1 | 2000 | 211 | 0.040 |
Why?
|
Dermatomycoses | 1 | 1999 | 48 | 0.040 |
Why?
|
Substance-Related Disorders | 2 | 2015 | 4419 | 0.040 |
Why?
|
Liver | 1 | 1995 | 7531 | 0.040 |
Why?
|
Drugs, Investigational | 1 | 2001 | 212 | 0.040 |
Why?
|
New York | 1 | 2001 | 874 | 0.040 |
Why?
|
Organizational Innovation | 1 | 2002 | 536 | 0.040 |
Why?
|
Haiti | 2 | 2014 | 550 | 0.040 |
Why?
|
Rifabutin | 1 | 1999 | 59 | 0.040 |
Why?
|
Seroepidemiologic Studies | 1 | 2020 | 397 | 0.040 |
Why?
|
Los Angeles | 1 | 2019 | 243 | 0.040 |
Why?
|
Clarithromycin | 1 | 1999 | 86 | 0.040 |
Why?
|
Organizations | 1 | 2019 | 171 | 0.040 |
Why?
|
Tumor Virus Infections | 1 | 2001 | 438 | 0.040 |
Why?
|
Eligibility Determination | 1 | 2002 | 421 | 0.040 |
Why?
|
Academic Medical Centers | 1 | 2008 | 2760 | 0.040 |
Why?
|
Ethics | 1 | 1998 | 94 | 0.040 |
Why?
|
Drug Resistance, Microbial | 1 | 2001 | 857 | 0.040 |
Why?
|
Canada | 1 | 2023 | 2120 | 0.040 |
Why?
|
History, 20th Century | 1 | 2006 | 2770 | 0.040 |
Why?
|
Administration, Oral | 2 | 2017 | 4013 | 0.040 |
Why?
|
Alanine | 1 | 2020 | 607 | 0.040 |
Why?
|
Malawi | 1 | 2019 | 304 | 0.040 |
Why?
|
RNA, Messenger | 1 | 2012 | 12787 | 0.040 |
Why?
|
Efficiency, Organizational | 1 | 2002 | 695 | 0.040 |
Why?
|
Azithromycin | 1 | 1999 | 199 | 0.040 |
Why?
|
Leukocyte Count | 2 | 1992 | 1597 | 0.040 |
Why?
|
Developed Countries | 2 | 2012 | 449 | 0.040 |
Why?
|
Intention | 1 | 2020 | 347 | 0.040 |
Why?
|
Hospitals, Teaching | 1 | 2002 | 1156 | 0.040 |
Why?
|
Chi-Square Distribution | 2 | 2001 | 3419 | 0.040 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2004 | 1783 | 0.040 |
Why?
|
Probability | 2 | 2005 | 2478 | 0.040 |
Why?
|
Viral Proteins | 1 | 2004 | 1803 | 0.030 |
Why?
|
Neural Tube Defects | 1 | 2019 | 254 | 0.030 |
Why?
|
Electronic Health Records | 1 | 2014 | 4812 | 0.030 |
Why?
|
Pediatrics | 1 | 2012 | 3594 | 0.030 |
Why?
|
Deoxycytidine | 2 | 2013 | 875 | 0.030 |
Why?
|
Systems Analysis | 1 | 2017 | 169 | 0.030 |
Why?
|
Cytomegalovirus | 1 | 2001 | 756 | 0.030 |
Why?
|
Immunoglobulin M | 1 | 2001 | 1530 | 0.030 |
Why?
|
Immunization | 1 | 2021 | 1226 | 0.030 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2019 | 330 | 0.030 |
Why?
|
Occupational Diseases | 1 | 2004 | 1491 | 0.030 |
Why?
|
Nutrition Surveys | 1 | 2023 | 1728 | 0.030 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2001 | 4022 | 0.030 |
Why?
|
Nursing Homes | 1 | 2023 | 1081 | 0.030 |
Why?
|
Child, Orphaned | 1 | 2016 | 55 | 0.030 |
Why?
|
Protozoan Infections | 1 | 1995 | 38 | 0.030 |
Why?
|
Diet | 1 | 2014 | 8074 | 0.030 |
Why?
|
Costs and Cost Analysis | 2 | 2011 | 1668 | 0.030 |
Why?
|
Evolution, Molecular | 1 | 2004 | 1888 | 0.030 |
Why?
|
Dermatology | 1 | 2006 | 918 | 0.030 |
Why?
|
Sex Factors | 1 | 2009 | 10551 | 0.030 |
Why?
|
Population Surveillance | 1 | 2006 | 2603 | 0.030 |
Why?
|
Chronic Disease | 2 | 2011 | 9319 | 0.030 |
Why?
|
Cytodiagnosis | 1 | 1999 | 447 | 0.030 |
Why?
|
Papillomaviridae | 1 | 2001 | 1119 | 0.030 |
Why?
|
Urban Health | 2 | 2008 | 533 | 0.030 |
Why?
|
Nicotine | 1 | 2020 | 680 | 0.030 |
Why?
|
Opiate Substitution Treatment | 1 | 2019 | 443 | 0.030 |
Why?
|
Paclitaxel | 1 | 2022 | 1732 | 0.030 |
Why?
|
Administration, Topical | 1 | 2017 | 703 | 0.030 |
Why?
|
Internship and Residency | 2 | 2011 | 5877 | 0.030 |
Why?
|
Chelation Therapy | 1 | 1995 | 77 | 0.030 |
Why?
|
Clinical Protocols | 2 | 2009 | 1440 | 0.030 |
Why?
|
Africa, Eastern | 1 | 2014 | 76 | 0.030 |
Why?
|
Postpartum Period | 1 | 2001 | 1172 | 0.030 |
Why?
|
Fees, Medical | 1 | 1994 | 111 | 0.030 |
Why?
|
Edetic Acid | 1 | 1995 | 283 | 0.030 |
Why?
|
Homosexuality | 2 | 2009 | 267 | 0.030 |
Why?
|
Portugal | 1 | 2013 | 91 | 0.030 |
Why?
|
Blood Proteins | 1 | 1979 | 1180 | 0.030 |
Why?
|
Electrolytes | 1 | 1994 | 274 | 0.030 |
Why?
|
Prenatal Care | 1 | 2001 | 1139 | 0.030 |
Why?
|
Truth Disclosure | 1 | 1998 | 434 | 0.030 |
Why?
|
Cholesterol | 1 | 2002 | 2902 | 0.030 |
Why?
|
Focus Groups | 1 | 2019 | 1414 | 0.030 |
Why?
|
Health Status | 2 | 2003 | 4075 | 0.030 |
Why?
|
Pain Measurement | 1 | 2003 | 3552 | 0.030 |
Why?
|
Lung Neoplasms | 1 | 2017 | 13333 | 0.030 |
Why?
|
Single-Blind Method | 1 | 2017 | 1571 | 0.030 |
Why?
|
Streptomycin | 1 | 2012 | 70 | 0.030 |
Why?
|
Kanamycin | 1 | 2012 | 64 | 0.030 |
Why?
|
Therapy, Computer-Assisted | 1 | 1995 | 266 | 0.030 |
Why?
|
Perception | 1 | 2019 | 1197 | 0.030 |
Why?
|
Pilot Projects | 2 | 2005 | 8632 | 0.030 |
Why?
|
Blood Specimen Collection | 1 | 1994 | 238 | 0.030 |
Why?
|
Precancerous Conditions | 1 | 1999 | 978 | 0.030 |
Why?
|
Recombinant Proteins | 3 | 2008 | 6525 | 0.020 |
Why?
|
Models, Organizational | 1 | 1995 | 546 | 0.020 |
Why?
|
Urinalysis | 1 | 2014 | 368 | 0.020 |
Why?
|
National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2011 | 62 | 0.020 |
Why?
|
Patient Preference | 1 | 2019 | 926 | 0.020 |
Why?
|
Exercise Test | 1 | 1999 | 2129 | 0.020 |
Why?
|
Confidence Intervals | 2 | 2010 | 2927 | 0.020 |
Why?
|
Infection Control | 1 | 2019 | 985 | 0.020 |
Why?
|
Analysis of Variance | 3 | 2013 | 6231 | 0.020 |
Why?
|
Research Design | 2 | 2020 | 6178 | 0.020 |
Why?
|
Insurance, Health, Reimbursement | 1 | 1994 | 385 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 4567 | 0.020 |
Why?
|
Causality | 1 | 2017 | 1243 | 0.020 |
Why?
|
Blood Gas Analysis | 1 | 1992 | 379 | 0.020 |
Why?
|
Hospitals, Rural | 1 | 2012 | 175 | 0.020 |
Why?
|
Sickness Impact Profile | 1 | 2012 | 299 | 0.020 |
Why?
|
Reference Standards | 1 | 2014 | 1004 | 0.020 |
Why?
|
Hospitals, Urban | 1 | 2012 | 500 | 0.020 |
Why?
|
Medical Staff, Hospital | 1 | 1994 | 601 | 0.020 |
Why?
|
Emergency Service, Hospital | 1 | 2010 | 7872 | 0.020 |
Why?
|
Social Support | 2 | 2017 | 2172 | 0.020 |
Why?
|
District of Columbia | 1 | 2010 | 159 | 0.020 |
Why?
|
Family Characteristics | 1 | 2015 | 1003 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2010 | 3806 | 0.020 |
Why?
|
HLA-C Antigens | 1 | 2010 | 147 | 0.020 |
Why?
|
HLA-A Antigens | 1 | 2010 | 226 | 0.020 |
Why?
|
Vulnerable Populations | 1 | 2015 | 702 | 0.020 |
Why?
|
Drug Administration Routes | 1 | 2010 | 150 | 0.020 |
Why?
|
CD4-CD8 Ratio | 1 | 2009 | 114 | 0.020 |
Why?
|
False Negative Reactions | 1 | 2011 | 573 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2017 | 2426 | 0.020 |
Why?
|
Family | 1 | 2020 | 3197 | 0.020 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2011 | 239 | 0.020 |
Why?
|
Papillomavirus Infections | 1 | 2001 | 1610 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2001 | 4550 | 0.020 |
Why?
|
Sexual Partners | 1 | 2014 | 796 | 0.020 |
Why?
|
Virus Diseases | 1 | 1995 | 719 | 0.020 |
Why?
|
Clinical Trials, Phase IV as Topic | 1 | 2009 | 29 | 0.020 |
Why?
|
Data Mining | 1 | 2014 | 551 | 0.020 |
Why?
|
Selection, Genetic | 2 | 2004 | 870 | 0.020 |
Why?
|
Hospitals, University | 1 | 2011 | 564 | 0.020 |
Why?
|
Drug Tolerance | 1 | 1991 | 367 | 0.020 |
Why?
|
Contact Tracing | 1 | 2011 | 271 | 0.020 |
Why?
|
Consent Forms | 1 | 2009 | 55 | 0.020 |
Why?
|
Alleles | 2 | 2010 | 6909 | 0.020 |
Why?
|
Socioeconomic Factors | 2 | 2013 | 7824 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2017 | 10203 | 0.020 |
Why?
|
Bottle Feeding | 1 | 2008 | 67 | 0.020 |
Why?
|
Cell Count | 1 | 2013 | 1835 | 0.020 |
Why?
|
Qualitative Research | 1 | 2019 | 3025 | 0.020 |
Why?
|
Medical Record Linkage | 1 | 2010 | 285 | 0.020 |
Why?
|
Models, Immunological | 1 | 2010 | 512 | 0.020 |
Why?
|
Cough | 1 | 1992 | 594 | 0.020 |
Why?
|
Aerosols | 1 | 1991 | 635 | 0.020 |
Why?
|
Radiography, Thoracic | 1 | 1994 | 1303 | 0.020 |
Why?
|
Lead | 1 | 1994 | 879 | 0.020 |
Why?
|
Drug Resistance, Multiple, Bacterial | 1 | 2012 | 589 | 0.020 |
Why?
|
Jamaica | 1 | 2007 | 54 | 0.020 |
Why?
|
Fractures, Bone | 1 | 2020 | 2046 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2011 | 1704 | 0.020 |
Why?
|
Triage | 1 | 1994 | 986 | 0.020 |
Why?
|
Kidney Failure, Chronic | 1 | 2020 | 2471 | 0.020 |
Why?
|
Pregnancy Complications | 1 | 2001 | 2947 | 0.020 |
Why?
|
Caribbean Region | 1 | 2007 | 191 | 0.020 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2001 | 3441 | 0.020 |
Why?
|
Echocardiography | 1 | 1999 | 4991 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2010 | 4576 | 0.020 |
Why?
|
Bayes Theorem | 1 | 2014 | 2329 | 0.020 |
Why?
|
Antipsychotic Agents | 1 | 1979 | 3067 | 0.020 |
Why?
|
Poisson Distribution | 1 | 2007 | 504 | 0.020 |
Why?
|
Health Promotion | 1 | 2017 | 2213 | 0.020 |
Why?
|
Interviews as Topic | 2 | 2003 | 2696 | 0.020 |
Why?
|
Linear Models | 3 | 2003 | 5871 | 0.020 |
Why?
|
HLA-A3 Antigen | 1 | 2004 | 34 | 0.010 |
Why?
|
Language | 1 | 2014 | 1539 | 0.010 |
Why?
|
Virology | 1 | 2005 | 75 | 0.010 |
Why?
|
Georgia | 1 | 2005 | 185 | 0.010 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2009 | 857 | 0.010 |
Why?
|
Caregivers | 1 | 2017 | 2235 | 0.010 |
Why?
|
Amino Acids | 1 | 2010 | 1718 | 0.010 |
Why?
|
Health Personnel | 2 | 2011 | 3335 | 0.010 |
Why?
|
Survivors | 1 | 1995 | 2370 | 0.010 |
Why?
|
Haplotypes | 1 | 2010 | 2774 | 0.010 |
Why?
|
Temperance | 1 | 2004 | 87 | 0.010 |
Why?
|
Dyspnea | 1 | 1992 | 1344 | 0.010 |
Why?
|
Sequence Analysis, RNA | 1 | 2012 | 2019 | 0.010 |
Why?
|
Review Literature as Topic | 1 | 2006 | 347 | 0.010 |
Why?
|
Chickenpox Vaccine | 1 | 2003 | 40 | 0.010 |
Why?
|
Investments | 1 | 2005 | 147 | 0.010 |
Why?
|
HIV Protease | 1 | 2003 | 97 | 0.010 |
Why?
|
gag Gene Products, Human Immunodeficiency Virus | 1 | 2004 | 206 | 0.010 |
Why?
|
Patient Education as Topic | 1 | 2013 | 2319 | 0.010 |
Why?
|
Immunodominant Epitopes | 1 | 2004 | 240 | 0.010 |
Why?
|
Blotting, Western | 1 | 2011 | 5034 | 0.010 |
Why?
|
Interferon-gamma | 1 | 2011 | 3159 | 0.010 |
Why?
|
Protein Conformation | 1 | 2010 | 3969 | 0.010 |
Why?
|
Body Constitution | 1 | 2002 | 273 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2012 | 5866 | 0.010 |
Why?
|
Molecular Sequence Data | 2 | 2004 | 17640 | 0.010 |
Why?
|
Meta-Analysis as Topic | 1 | 2006 | 1376 | 0.010 |
Why?
|
Attitude of Health Personnel | 1 | 1994 | 3889 | 0.010 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2004 | 825 | 0.010 |
Why?
|
Models, Molecular | 1 | 2010 | 5439 | 0.010 |
Why?
|
Pregnancy Outcome | 1 | 2011 | 2920 | 0.010 |
Why?
|
Acute Disease | 1 | 2011 | 7238 | 0.010 |
Why?
|
Mesoridazine | 1 | 1979 | 2 | 0.010 |
Why?
|
Drug Hypersensitivity | 1 | 2008 | 917 | 0.010 |
Why?
|
Hydroxylation | 1 | 1979 | 137 | 0.010 |
Why?
|
Chlorpromazine | 1 | 1979 | 111 | 0.010 |
Why?
|
Immunity, Innate | 1 | 2010 | 3060 | 0.010 |
Why?
|
Point Mutation | 1 | 2003 | 1595 | 0.010 |
Why?
|
Social Class | 1 | 2007 | 2005 | 0.010 |
Why?
|
Self Efficacy | 1 | 2002 | 637 | 0.010 |
Why?
|
Severity of Illness Index | 2 | 2007 | 15835 | 0.010 |
Why?
|
Medicare | 1 | 1994 | 6758 | 0.010 |
Why?
|
Body Mass Index | 1 | 2014 | 12949 | 0.010 |
Why?
|
Infection Control Practitioners | 1 | 1995 | 12 | 0.010 |
Why?
|
Phylogeny | 1 | 2003 | 2809 | 0.010 |
Why?
|
United States Public Health Service | 1 | 1995 | 31 | 0.010 |
Why?
|
Myocardial Revascularization | 1 | 1999 | 792 | 0.010 |
Why?
|
Drug Interactions | 1 | 2000 | 1415 | 0.010 |
Why?
|
Dyslexia, Acquired | 1 | 1995 | 14 | 0.010 |
Why?
|
Penicillamine | 1 | 1995 | 60 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2013 | 5841 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2006 | 5247 | 0.010 |
Why?
|
Matched-Pair Analysis | 1 | 1994 | 283 | 0.010 |
Why?
|
Hypertension | 1 | 2013 | 8539 | 0.010 |
Why?
|
Body Composition | 1 | 2002 | 2422 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2004 | 13446 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2003 | 4740 | 0.010 |
Why?
|
Base Sequence | 1 | 2003 | 12449 | 0.010 |
Why?
|
Education | 1 | 1995 | 536 | 0.010 |
Why?
|
Length of Stay | 1 | 2005 | 6422 | 0.010 |
Why?
|
Disease Outbreaks | 1 | 2001 | 1762 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2010 | 12666 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2010 | 15879 | 0.010 |
Why?
|
Adipose Tissue | 1 | 2002 | 3310 | 0.010 |
Why?
|
Protein Binding | 1 | 1979 | 9351 | 0.000 |
Why?
|
Life Style | 1 | 1998 | 3915 | 0.000 |
Why?
|
Mutation | 1 | 2009 | 30044 | 0.000 |
Why?
|
Societies, Medical | 1 | 1995 | 3905 | 0.000 |
Why?
|
Clinical Competence | 1 | 1994 | 4793 | 0.000 |
Why?
|
Myocardial Infarction | 1 | 1999 | 11454 | 0.000 |
Why?
|
Animals | 1 | 2004 | 168388 | 0.000 |
Why?
|